D. Rischin

发表

Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.

J. Homsi, N. Khushalani, P. Swiecicki, 2023, The Lancet. Oncology.

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.